Clinical Experience with Nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007

Saurez, Giselle; Cabanas, Ricardo; Zaldívar, Melba; Garnier, T; Iglesias, Bárbara; Piedra, Patricia; Castillo, Martha Ríos; Longchong, M.; Iznaga, Normando; Lage, Agustín

doi:10.37757/mr2009v11.n3.7

Cited by 16 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Druggable targets can be found in a considerable proportion of patients with pHGG, and personalized treatment concepts may offer benefits for selected patients, where prolonged survival and tumor responses can be observed, even in DIPG [8,14,15,22,24,33,[37][38][39]. However, apart from high-priority targets such as BRAF-, ALK-, ROS-or NTRKalterations, evidence is still limited for most therapeutic options.…”

Section: Discussionmentioning

confidence: 99%

How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study

Perwein

Giese²,

Nussbaumer³

et al. 2023

J Neurooncol

View full text Add to dashboard Cite

Purpose As there is no standard of care treatment for recurrent/progressing pediatric high-grade gliomas (pHGG), we aimed to gain an overview of different treatment strategies. Methods In a web-based questionnaire, members of the SIOPE-BTG and the GPOH were surveyed on therapeutic options in four case scenarios (children/adolescents with recurrent/progressing HGG). Results 139 clinicians with experience in pediatric neuro-oncology from 22 European countries participated in the survey. Most respondents preferred further oncological treatment in three out of four cases and chose palliative care in one case with marked symptoms. Depending on the case, 8–92% would initiate a re-resection (preferably hemispheric pHGG), combined with molecular diagnostics. Throughout all case scenarios, 55–77% recommended (re-)irradiation, preferably local radiotherapy > 20 Gy. Most respondents would participate in clinical trials and use targeted therapy (79–99%), depending on molecular genetic findings (BRAF alterations: BRAF/MEK inhibitor, 64–88%; EGFR overexpression: anti-EGFR treatment, 46%; CDKN2A deletion: CDK inhibitor, 18%; SMARCB1 deletion: EZH2 inhibitor, 12%). 31–72% would administer chemotherapy (CCNU, 17%; PCV, 8%; temozolomide, 19%; oral etoposide/trofosfamide, 8%), and 20–69% proposed immunotherapy (checkpoint inhibitors, 30%; tumor vaccines, 16%). Depending on the individual case, respondents would also include bevacizumab (6–18%), HDAC inhibitors (4–15%), tumor-treating fields (1–26%), and intraventricular chemotherapy (4–24%). Conclusion In each case, experts would combine conventional multimodal treatment concepts, including re-irradiation, with targeted therapy based on molecular genetic findings. International cooperative trials combining a (chemo-)therapy backbone with targeted therapy approaches for defined subgroups may help to gain valid clinical data and improve treatment in pediatric patients with recurrent/progressing HGG.

show abstract